Filing Flows › TG Therapeutics (TGTX) › Q1 2026 › vs Q1 2025
TG Therapeutics (TGTX) Q1 2026 vs Q1 2025 (year over year)
TG Therapeutics's revenue rose $84.1M (+70%) from $121M in Q1 2025 to $205M in Q1 2026. The biggest changes: Product +$81.7M (+68%); License +$2.4M (+201%). Operating margin 17.0% against 7.1% (+9.8 pts).
TG Therapeutics, Q1 2026: revenue $205M (+70% year over year), operating margin 17.0%, net earnings $19.8M, operating cash flow −$17.9M. The chart draws each line against Q1 2025, the increases inside each band.
Margins
| Q1 2026 | Q1 2025 | Change | |
|---|---|---|---|
| Operating margin | 17.0% | 7.1% | +9.8 pts |
| Net margin | 9.7% | 4.2% | +5.5 pts |
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Product | $201M | $120M | $81.7M | +68% |
| License | $3.6M | $1.2M | $2.4M | +201% |
| Revenue | $205M | $121M | $84.1M | +70% |
| Operating profit | $34.8M | $8.6M | $26.2M | +304% |
| Costs & expenses | $170M | $112M | $57.9M | +52% |
| Pre-tax earnings | $20.4M | $5.5M | $14.9M | +272% |
| Other expense, net | $14.4M | $3.2M | $11.3M | +358% |
| Cost of revenue | $33.5M | $15.5M | $18.0M | +116% |
| Research & development | $48.4M | $46.4M | $2.0M | +4% |
| SG&A | $88.2M | $50.3M | $37.9M | +75% |
| Net earnings | $19.8M | $5.1M | $14.7M | +291% |
| Income tax | $586K | $408K | $178K | +44% |
| Operating cash sources | $57.7M | $48.8M | $8.9M | +18% |
| Depreciation & amortization | $32K | $8K | $24K | +300% |
| Share-based compensation | $19.9M | $15.0M | $5.0M | +33% |
| Cash used in operations | $17.9M | $28.7M | −$10.8M | -38% |
| Working capital & other | $57.7M | $48.8M | $8.9M | +18% |
Questions
How much did TG Therapeutics's revenue grow year over year in Q1 2026?
TG Therapeutics's revenue rose $84.1M (+70%) from $121M in Q1 2025 to $205M in Q1 2026.
What drove TG Therapeutics's revenue change in Q1 2026?
Product +$81.7M (+68%); License +$2.4M (+201%).